Evaluation of programmed death ligand-1 (PD-L1) expression via immunohistochemistry (IHC) is currently the only FDA-approved molecular test for cancer patient selection for immune checkpoint blockade (ICB) therapy (1–3). The gene discussed is CD274; the disease is cancer.